Genetic Technologies Limited (GENE) Quarterly Balance Sheets

Quarterly · GAAP · USD millions
Access GENE Annual Balance Sheets →
A period-by-period view of the balance sheet from Genetic Technologies Limited to Jun 30 2023 helps clarify how Jun 30 2024's financial structure has changed over time.
Quarterly Report, GAAP in USD millions
ITEM
(Jun 30 2024)
0 0 0 (Jun 30 2023)
Assets
Cash And Cash Equivalents0.68
Cash & Short-term Investments0.00
Accounts receivable0.14
Trade & Other Current Receivables (IFRS combined total)-
Inventories0.14
Other Current Assets1.51
Total Current Assets2.47
Equipment/Property/Plant Net0.04
Goodwill net1.19
Deferred Tax Assets0.05
Other Assets, Noncurrent0.38
Total Assets4.13
Liabilities
Accounts Payable1.36
Other Liabilities, Current1.06
Current Provisions0.38
Total Current Liabilities2.80
Total Long-term Debt0.00
Deferred Tax Liabilities, Net LI0.05
Noncurrent Provisions0.05
Total Liabilities2.91
Stockholders' Equity
Other Equity1.22
Common Stockholder's Equity1.22
Total Stockholder's Equity1.22
Liabilities & Stockholder's Equity4.13
4 historic quarters locked

Sign in to unlock the full Genetic Technologies Limited balance sheet history.

About Genetic Technologies Ltd Quarterly Balance Sheet

What this statement shows

This page presents issuer-reported balance sheet data, detailing assets, liabilities, and stockholders equity as reported in SEC 20-F filings and standardized by CSIMarket. The balance sheet reflects the company's financial position at the end of each reporting period.

Source & verification

  • Form: 20-F (Period: 20240630)
  • Filed with the SEC: September 30, 2024
  • Source: form20-f.htm

Last updated

  • Page updated:
  • Data lineage: SEC filings - XBRL extraction - balance-sheet normalization in the CSIMarket.com financial database.
  • Accession: 0001493152-24-038693

Balance sheet figures represent financial position at specific reporting dates and may be revised in subsequent filings.